Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

BACKGROUND: This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV infected patients that were previously exposed to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hubben, Gijs AA, Bos, Jasper M, Veltman-Starkenburg, Christa A, Stegmeijer, Simon, Finnern, Henrik W, Kappelhoff, Bregt S, Simpson, Kit N, Tramarin, Andrea, Postma, Maarten J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211743/
https://www.ncbi.nlm.nih.gov/pubmed/18034881
http://dx.doi.org/10.1186/1478-7547-5-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211743/
https://www.ncbi.nlm.nih.gov/pubmed/18034881
http://dx.doi.org/10.1186/1478-7547-5-15

Ejemplares similares